GOFD hydrogel capable of being used for treating radioactive skin injury as well as preparation and application of GOFD hydrogel

Abstract

The invention discloses GOFD hydrogel capable of being used for treating radioactive skin injury as well as preparation and application of the GOFD hydrogel. The GOFD hydrogel is obtained by self-assembly of polydopamine modified graphene oxide, a basic fibroblast growth factor FGF2, a single-stranded DNA (deoxyribonucleic acid) Y1, a single-stranded DNA Y2, a single-stranded DNA Y3, a single-stranded DNA L4 and a single-stranded DNA L5. The GOFD hydrogel not only can play a role in mechanically supporting and filling wounds, but also has obvious cell migration promoting activity and antioxidant activity, can effectively promote generation of blood vessels of damaged parts and healing of the damaged parts, and has wide market prospects in preparation of radiation protective agents and medicines for treating radiation skin injuries.

Description

Technical Field

[0001] The invention belongs to the technical field of hydrogels, and in particular relates to a GOFD hydrogel that can be used for treating radiation skin damage, and a preparation method and application thereof. Background Art

[0002] Radiotherapy is a very common and effective treatment method in modern medicine. Radiotherapy of cancer sites is one of the mainstream tumor intervention measures to inhibit tumors. However, during radiotherapy, undesirable radiation damage will inevitably occur due to the high radiation equivalent dose of the irradiated adjacent normal tissues exceeding their own tolerance. Among them, radiation skin damage is one of the common but debilitating side effects. 95% of cancer patients will experience varying degrees of radiation skin damage after radiotherapy. And with the accumulation of irradiation times and doses, the clinical and pathological manifestations of radiation dermatitis are initially erythema and dry peeling, which develop into wet peeling and even skin necrosis in severe cases. These radiation-induced skin injuries may lead to susceptibility to cross-infection, causing skin lesions, a decrease in the patient's quality of life, and in severe cases, interruption of tumor treatment. In irradiation radiotherapy, high-energy ionizing radiation X-rays are mainly used. X-rays can directly cause DNA damage and produce a large amount of reactive oxygen by reacting with water. Excessive reactive oxygen will further damage the epidermal basal cells, and the destruction of the epidermal basal cells has a serious impact on the normal metabolism and regeneration function of skin tissue. According to the damage mechanism of radiation dermatitis, there is an urgent need for a free radical scavenger as an effective skin radiation protector to remove the excess ROS produced by X-rays, thereby blocking the development of radiation skin damage from the source and accelerating the healing of existing wounds.

[0003] The current hydrogel dressing technology for treating radiation-induced skin injury wounds has the following main problems: first, the biocompatibility of hydrogel dressings for wound treatment is generally poor; second, most of the existing hydrogel dressings are mainly used to reduce infection and relieve local symptoms, lack biological activity, and cannot effectively promote the healing of radiation-induced skin injury wounds at the molecular level; third, most of the existing hydrogels lack antibacterial and anti-reactive oxygen properties and cannot protect the wound well. Summary of the invention

[0004] In order to solve the above problems, the present invention provides a GOFD hydrogel that can be used for treating radiation skin damage and its preparation and application.

[0005] To achieve the above object, the present invention provides the following technical solutions: The first aspect of the present invention provides a GOFD hydrogel that can be used for treating radiation skin damage, wherein the GOFD hydrogel is self-assembled from polydopamine-modified graphene oxide, basic fibroblast growth factor FGF2, single-stranded DNAY1, single-stranded DNAY2, single-stranded DNAY3, single-stranded DNAL4 and single-stranded DNAL5; The nucleotide sequence of single-stranded DNA Y1 is: 5'-ACTTGACTTAACTCATAGTTATCATGCACGCGATCGATCGTTAATGATATTACGTGATATCGA-3', The nucleotide sequence of single-stranded DNA Y2 is: 5'-ACTTGACTTAACTTCGATATCACGTAATATCATTAACGACCGATCATTCCGTGAGCGTTAACG-3', The nucleotide sequence of single-stranded DNA Y3 is: 5'-ACTTGACTTAACTCGTTAACGCTCACGGAATGATCGGTATCGATCGCGTGCATGATAACTATG-3', The nucleotide sequence of single-stranded DNA L4 is: 5'-AGTTAAGTCAAGTTGAGGTAGACTTAACTATCT-3', and the nucleotide sequence of single-stranded DNA L5 is: 5'-AGTTAAGTCAAGTAGATAGTTAAGTCTACCTCA-3'.

[0006] The second aspect of the present invention provides a method for preparing the above-mentioned GOFD hydrogel, comprising the following steps: S1: adding graphene oxide to Tris buffer, ultrasonicating in a water bath at room temperature for 2 h, then adding dopamine, stirring at room temperature for 48 h, centrifuging, washing the obtained precipitate with distilled water and 95 vol% ethanol respectively, and then drying at 40°C to obtain polydopamine-modified graphene oxide; S2: Mix single-stranded DNA Y1, single-stranded DNA Y2 and single-stranded DNA Y3 in PBS buffer, keep at 95°C for 2 min, and then cool to 25°C at a rate of 0.1°C / 0.06s to obtain a Y monomer solution; S3: Mix the single-stranded DNA L4 and the single-stranded DNA L5 in PBS buffer, keep at 95°C for 2 min, and then cool to 25°C at a rate of 0.1°C / 0.06s to obtain an L monomer solution; S4: Mix the Y monomer solution and the basic fibroblast growth factor FGF2 solution at 20-35°C for 2 minutes to obtain product A; mix the L monomer solution and the polydopamine-modified graphene oxide solution at 20°C for 2 minutes to obtain product B; stir and mix product A and product B at 20°C for 1 minute to obtain GOFD hydrogel that can be used for the treatment of radiation skin damage; In step S1, the mass ratio of graphene oxide to dopamine is 1:1; In step S2, the molar ratio of single-stranded DNA Y1, single-stranded DNA Y2 and single-stranded DNA Y3 is 1:1:1; In step S3, the molar ratio of single-stranded DNA L4 to single-stranded DNA L5 is 1:1; In step S4, the content of Y monomer in the GOFD hydrogel is 250-500 μmol / L, the content of basic fibroblast growth factor FGF2 in the GOFD hydrogel is 0.5-1 ng / μL, the content of L monomer in the GOFD hydrogel is 375-700 μmol / L, and the content of polydopamine-modified graphene oxide in the GOFD hydrogel is 0.05-0.15 mg / ml.

[0007] The third aspect of the present invention provides an application of the above-mentioned GOFD hydrogel, which is any one or more of the following: 1) Application in the preparation of drugs for promoting cell migration; 2) Application in the preparation of antioxidant drugs; 3) Application in the preparation of drugs for promoting angiogenesis; 4) Application in the preparation of radioprotective agents; 5) Application in the preparation of drugs for treating radiation-induced skin damage.

[0008] The significant advantages of the present invention are: a) The present invention is the first to use basic fibroblast growth factor FGF2 as a wound healing material for radiation-induced skin damage, encapsulate basic fibroblast growth factor FGF2 and polydopamine-modified graphene oxide into a physically cross-linked DNA hydrogel, and develop a multifunctional DNA gel with strong shape adaptability, biodegradability, biocompatibility, antioxidant and immunomodulatory properties. It is the first time that DNA hydrogel is used to treat radiation-induced skin damage, with minimal cytotoxicity, non-immunogenicity and satisfactory biocompatibility.

[0009] b) The preparation process of the GOFD hydrogel of the present invention is simple. The GOFD hydrogel is loaded with basic fibroblast growth factor FGF2 and polydopamine-modified graphene oxide, and has antioxidant capacity. When the DNA hydrogel is used for wound healing treatment, the excessive reactive oxygen in the wound can be effectively removed, thereby promoting wound healing and recovery.

[0010] c) The GOFD hydrogel of the present invention has a sustained-release effect on basic fibroblast growth factor FGF2, which can improve the short half-life and poor stability of basic fibroblast growth factor FGF2 itself. A single dose can maintain the concentration of basic fibroblast growth factor FGF2 in the wound for a long time to meet the conditions of continuous anti-inflammatory and promotion of wound healing, reduce the medication cycle, and improve the therapeutic effect that can be achieved by a single dose.

[0011] d) The GOFD hydrogel of the present invention can self-degrade during the treatment process. The GOFD hydrogel has good biocompatibility. The physically cross-linked hydrogel itself is relatively soft and can adapt to irregular wounds of various shapes and depths without causing further mechanical damage. It also provides a scaffold for the cells of the new tissue.

[0012] e) The present invention constructs a hydrogel through Y monomer and L monomer, the method is relatively mature, the operation steps are simple, and the judgment result is highly reliable. BRIEF DESCRIPTION OF THE DRAWINGS

[0013] Figure 1 : Flow chart of the preparation of GOFD hydrogel.

[0014] Figure 2 : TEM image of polydopamine modified graphene oxide.

[0015] Figure 3 : Actual picture of GOFD hydrogel.

[0016] Figure 4 : Cell migration promoting activity of GOFD hydrogel.

[0017] Figure 5 : In vitro antioxidant activity of GOFD hydrogel.

[0018] Figure 6 : Intracellular antioxidant activity of GOFD hydrogel.

[0019] Figure 7 : In vitro angiogenesis-promoting ability of GOFD hydrogel.

[0020] Figure 8 : Graph of the radioprotective ability of GOFD hydrogel.

[0021] Fig. 9: Experimental results of GOFD hydrogel in radiation protection and injury healing in animal models. DETAILED DESCRIPTION

[0022] In order to make the purpose, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention. Therefore, the following detailed description of the embodiments of the present invention provided in the drawings is not intended to limit the scope of the invention claimed for protection, but merely represents the selected embodiments of the present invention. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.

[0023] The nucleotide sequences of the single-stranded DNA involved in the following embodiments are as follows: Y1: 5'-ACTTGACTTAACTCATAGTTATCATGCACGCGATCGATCGTTAATGATATTACGTGATATCGA-3', Y2: 5'-ACTTGACTTAACTTCGATATCACGTAATATCATTAACGACCGATCATTCCGTGAGCGTTAACG-3', Y3: 5'-ACTTGACTTAACTCGTTAACGCTCACGGAATGATCGGTATCGATCGCGTGCATGATAACTATG-3', L4: 5'-AGTTAAGTCAAGTTGAGGTAGACTTAACTATCT-3', L5: 5'-AGTTAAGTCAAGTAGATAGTTAAGTCTACCTCA-3'.

[0024] Embodiment 1: This embodiment provides a method for preparing a GOFD hydrogel, and the steps are as follows: S1: Preparation of polydopamine-modified graphene oxide: 30 mg of graphene oxide was added to Tris buffer (10 mM, pH 8.5), ultrasonicated in a water bath at room temperature for 2 h, then 30 mg of dopamine was added, stirred at room temperature for 48 h, and centrifuged at 8000 rpm for 10 min. The obtained precipitate was washed three times with distilled water and 95 vol% ethanol, respectively, and then dried in an oven at 40 ° C for 12 h to obtain polydopamine-modified graphene oxide (GO@PDA).

[0025] S2: Preparation of Y monomer: Y1 was prepared into a 250 μM solution with 1× PBS buffer (pH 7.2), Y2 was prepared into a 250 μM solution with 1× PBS buffer (pH 7.2), and Y3 was prepared into a 250 μM solution with 1× PBS buffer (pH 7.2); Y1 solution, Y2 solution and Y3 solution were mixed in a volume ratio of 1:1:1, kept at 95°C for 2 min, and then cooled to 25°C at a rate of 0.1°C / 0.06s to obtain a 160 μM Y monomer solution.

[0026] S3: Preparation of L monomer: L4 was prepared into a solution with a concentration of 375 μM using 1× PBS buffer (pH 7.2), and L5 was prepared into a solution with a concentration of 375 μM using 1× PBS buffer (pH 7.2); L4 solution and L5 solution were mixed in a volume ratio of 1:1, kept at 95°C for 1 min, and then cooled to 25°C at a rate of 0.1°C / 0.06s to obtain a 240 μM L monomer solution.

[0027] S4: Preparation of hydrogel: 24 μL of 160 μM Y monomer solution and 1 μL of 1 ng / μL basic fibroblast growth factor FGF2 solution were mixed and incubated at 20°C for 2 min to obtain product A; 24 μL of 240 μM L monomer solution and μL of 0.1 mg / mL polydopamine modified graphene oxide solution were mixed and incubated at 20°C for 2 min to obtain product B; the obtained products A and B were stirred and mixed at 20°C for 1 min until the mixture was in a gel state to obtain GOFD hydrogel.

[0028] Figure 1 Schematic diagram of the preparation process of GOFD hydrogel. Figure 2 This is the TEM image of polydopamine-modified graphene oxide. It can be seen from the figure that polydopamine-modified graphene oxide has a typical transparent and wrinkled flake structure with a particle size of about 1 μm. Figure 3 This is a physical picture of GOFD hydrogel.

[0029] Comparative Example: This comparative example provides a method for preparing a DNA hydrogel, and the steps are as follows: S1: Preparation of Y monomer: Y1 was prepared into a 250 μM solution with 1× PBS buffer (pH 7.2), Y2 was prepared into a 250 μM solution with 1× PBS buffer (pH 7.2), and Y3 was prepared into a 250 μM solution with 1× PBS buffer (pH 7.2); Y1 solution, Y2 solution and Y3 solution were mixed in a volume ratio of 1:1:1, kept at 95°C for 2 min, and then cooled to 25°C at a rate of 0.1°C / 0.06s to obtain a 160 μM Y monomer solution.

[0030] S2: Preparation of L monomer: L4 was prepared into a solution with a concentration of 375 μM using 1× PBS buffer (pH 7.2), and L5 was prepared into a solution with a concentration of 375 μM using 1× PBS buffer (pH 7.2); L4 solution and L5 solution were mixed in a volume ratio of 1:1, kept at 95°C for 1 min, and then cooled to 25°C at a rate of 0.1°C / 0.06s to obtain a 240 μM L monomer solution.

[0031] S3: Preparation of hydrogel: 160 μM Y monomer solution and 240 μM L monomer solution were mixed in a volume ratio of 1:1 and stirred at 20° C. for 1 to 2 min until the mixture was in a gel state to obtain a DNA hydrogel.

[0032] Embodiment 2: HacaT cells in logarithmic growth phase were cultured at 5 × 10 5 The cells were inoculated at a density of in a 6-well plate. When the cell growth in the 6-well plate reached a coverage rate of 90%, a sterile micropipette tip was used to gently scratch the cells perpendicular to the bottom of the well to produce vertical scratches. The cells were then co-cultured with DMEM medium containing GOFD hydrogel, and DMEM medium without GOFD hydrogel was used as a blank control group. After co-culture for 0h, 24h and 48h, the cell scratch area was observed and photographed with an optical microscope, and the cell migration rate was calculated using Image J software. Cell migration rate at 24h = (scratch area at 0h - scratch area at 24h) / scratch area at 0h. Cell migration rate at 48h = (scratch area at 0h - scratch area at 48h) / scratch area at 0h. Figure 4 As shown in the figure, the cell migration rate of the GOFD hydrogel-treated group at 24h increased by 1.48 times compared with the blank control group, and the cell migration rate of the GOFD hydrogel-treated group at 48h increased by 1.41 times compared with the blank control group, indicating that GOFD hydrogel has a good ability to promote cell migration.

[0033] Embodiment 3: Mix 2.84 g / L ABTS ethanol solution and 0.664 g / L potassium persulfate solution in a volume ratio of 1:1, and then place in the dark for 15 hours to obtain ABTS mother solution. Before the experiment, dilute it with anhydrous ethanol to an absorbance of 0.7±0.02 at 734 nm to make it an ABTS working solution. At the same time, prepare GOFD hydrogel and SOD, a commonly used drug on the market, for comparison. Mix 100 μL ABTS working solution with 100 μL ultrapure water as the control group; mix 100 μL ABTS working solution with 100 μL GOFD hydrogel and 100 μL SOD sample solution respectively as the experimental group. After incubating at room temperature in the dark for 10 minutes, use a UV-visible spectrophotometer to measure the absorption spectrum curves of all groups of solutions in the range of 500-900 nm. Use a 96-well plate for quantitative experiments, with 3 replicate wells in each group. The results are as follows. Figure 5 As shown in the figure, GOFD hydrogel has good antioxidant activity in vitro.

[0034] Embodiment 4: HaCaT cells were cultured at 1.5 × 10 5 The cells were seeded at a density of 100 μL / dish in a confocal dish and cultured for 24 hours; the cells were incubated with 100 μL PBS (Control), DNA hydrogel, GOFD hydrogel, GO@PDA and 1.5 mL of DMEM culture medium for 12 hours. After the incubation, the cells were washed 3 times with PBS, and then 1 mL of DMEM culture medium containing DCFH-DA probe (5 μL) was added to each dish (the concentration of the probe mother solution was 1 mg / mL), and the cells were placed in a 37°C incubator for another 20 minutes; the cells were washed 3 times with PBS to remove excess probes that did not enter the cells; the cells were then exposed to 6 Gy of X-rays at a dose of 1 Gy / min for 6 minutes; finally, CLSM was used to take pictures (using a 60× oil objective and a 488 nm laser). The results are shown in Figure 6 As shown, DNA hydrogel, GOFD hydrogel, and GO@PDA can effectively protect cells from radiation damage, and GOFD hydrogel has the best effect.

[0035] Embodiment 5: Pre-cool the 24-well plate and 1 mL pipette tip in a -20°C refrigerator, and melt the Matrigel matrix gel in advance in ice prepared by an ice maker; use the pre-cooled pipette tip to draw 250 μL of Matrigel matrix gel into the 24-well plate, taking care to avoid bubbles and ensure that the gel covers the bottom of the well (operate on an ice box); incubate the 24-well plate in a 37°C incubator for 30 minutes to allow the matrix gel to solidify evenly; during the waiting time for the matrix gel to solidify, digest the HUVEC cells, resuspend the cells with 1 mL of DMEM medium after centrifugation, and then add 100 μL PBS (Control), DNA hydrogel, GOFD hydrogel, and GO@PDA to mix with the cells; add 250 μL of cell suspension to each well, and the cell density is 5×10 4 / well, be careful not to generate bubbles and do not let the tip of the pipette touch the matrix gel; place the tubes in a cell culture incubator and culture for 24 hours, then take photos under a microscope to observe the tube formation. Figure 7 As shown, the number of tubes, number of grids, number of nodes and tube length of the GOFD hydrogel group were better than those of the other groups, indicating that the GOFD hydrogel group had a good ability to promote angiogenesis in vitro.

[0036] Embodiment 6: HaCaT cells in the logarithmic growth phase were digested and centrifuged and counted with a cell counter. Then, 2 × 10 3 The cells were inoculated in a 6-well plate at a density of 100 μL. The cells were shaken and placed in a cell culture incubator for 24 hours. The original culture medium was discarded and replaced with 1.5 mL DMEM culture medium and 100 μL GOFD hydrogel, after marking, was returned to the cell culture incubator and continued to be cultured for 24 hours; the culture medium containing the hydrogel solution was discarded and the cells were washed once with PBS, and then 1 mL of fresh DMEM complete culture medium was added to each well, and then the cells were exposed to a total dose of 6 Gy of X-rays at a dose rate of 1 Gy / min; the irradiated cells were continued to be cultured in the cell culture incubator, and the condition of the cells was observed during the culture process and the fresh culture medium was replaced in time according to the growth of the cells. After about 5 to 7 days, it was observed that the cells in the 6-well plate formed obvious cell clones visible to the naked eye, and the culture was terminated at this time; the original culture medium was discarded, and the cells were carefully washed once with PBS, and then the cells were fixed and stained with a volume fraction of 0.25% crystal violet stain (500 μL per well) for 30 minutes, and then the stain was discarded, and the 6-well plate was immersed in running water for 2 to 3 times, and then it was inverted on the table and left to dry naturally; the 6-well plate was inverted on the flat plate of the gel imager, and the clone plate was scanned and the image was collected using the gel imaging system. The results are as follows Figure 8 As shown, under the protection of GOFD hydrogel, the survival rate of cells is higher, indicating that GOFD hydrogel has excellent radiation protection ability.

[0037] Embodiment 7: After anesthesia (0.4% sodium pentobarbital intraperitoneally, anesthetized mice at a dose of 1 ml / 100 g body weight, 3% sodium pentobarbital, 1 mL / kg), the backs of BALB / c mice in the Control group and GOFD gel group were exposed to radiation at a set dose rate to irradiate a skin area of ​​1.0 cm × 1.0 cm. The total dose for each mouse was 50 Gy, and the irradiated site was marked and the hair at the site was removed. Subsequently, the wounds in the GOFD gel group were completely covered with GOFD gel hydrogel, and the wounds in the Control group were not covered with GOFD gel hydrogel. All surgical operations were performed in a sterilized room. The wound healing of the control group and the hydrogel-treated group was observed 4d, 9d, 16d, and 25d after administration. The wounds of each group were photographed, the wound size was measured, and the wound area was calculated. Fig. 9 As shown, compared with the Control group, the onset of radiation dermatitis in the GOFD gel group was delayed, the time from skin injury to recovery was relatively short, and hair recovery and hair growth were quite fast. This proves that GOFD hydrogel has good radiation protection and injury healing ability in animal models.

[0038] The above description is only a preferred embodiment of the present invention. All equivalent changes and modifications made according to the scope of the patent application of the present invention should fall within the scope of the present invention.

Claims

1. A GOFD hydrogel that can be used to treat radiation skin damage, characterized in that: The GOFD hydrogel is obtained by self-assembly of polydopamine-modified graphene oxide, basic fibroblast growth factor FGF2, single-stranded DNA Y1, single-stranded DNA Y2, single-stranded DNA Y3, single-stranded DNA L4 and single-stranded DNA L5; The nucleotide sequence of single-stranded DNA Y1 is: 5'-ACTTGACTTAACTCATAGTTATCATGCACGCGATCGATCGTTAATGATATTACGTGATATCGA-3', The nucleotide sequence of single-stranded DNA Y2 is: 5'-ACTTGACTTAACTTCGATATCACGTAATATCATTAACGACCGATCATTCCGTGAGCGTTAACG-3', The nucleotide sequence of single-stranded DNA Y3 is: 5'-ACTTGACTTAACTCGTTAACGCTCACGGAATGATCGGTATCGATCGCGTGCATGATAACTATG-3', The nucleotide sequence of single-stranded DNA L4 is: 5'-AGTTAAGTCAAGTTGAGGTAGACTTAACTATCT-3', The nucleotide sequence of the single-stranded DNA L5 is: 5'-AGTTAAGTCAAGTAGATAGTTAAGTCTACCTCA-3'.

2. The method for preparing the GOFD hydrogel according to claim 1, characterized in that: The steps include: S1: adding graphene oxide to Tris buffer, ultrasonicating in a water bath at room temperature for 2 h, then adding dopamine, stirring at room temperature for 48 h, centrifuging, washing the obtained precipitate with distilled water and 95 vol% ethanol respectively, and then drying at 40°C to obtain polydopamine-modified graphene oxide; S2: Mix single-stranded DNA Y1, single-stranded DNA Y2 and single-stranded DNA Y3 in PBS buffer, keep at 95°C for 2 min, and then cool to 25°C at a rate of 0.1°C / 0.06s to obtain a Y monomer solution; S3: Mix the single-stranded DNA L4 and the single-stranded DNA L5 in PBS buffer, keep at 95°C for 2 min, and then cool to 25°C at a rate of 0.1°C / 0.06s to obtain L monomer solution; S4: Mix the Y monomer solution and the basic fibroblast growth factor FGF2 solution at 20-35°C for 2 minutes to obtain product A; mix the L monomer solution and the polydopamine-modified graphene oxide solution at 20°C for 2 minutes to obtain product B; Product A and product B were stirred and mixed at 20° C. for 1 min to obtain a GOFD hydrogel that can be used to treat radiation skin damage.

3. The method according to claim 2, characterized in that: In step S1, the mass ratio of graphene oxide to dopamine is 1:

1.

4. The method according to claim 2, characterized in that: In step S2, the molar ratio of single-stranded DNA Y1, single-stranded DNA Y2 and single-stranded DNA Y3 is 1:1:

1.

5. The method according to claim 2, characterized in that: In step S3, the molar ratio of the single-stranded DNA L4 to the single-stranded DNA L5 is 1:

1.

6. The method according to claim 2, characterized in that: In step S4, the content of Y monomer in the GOFD hydrogel is 250~500 μmol / L, the content of basic fibroblast growth factor FGF2 in the GOFD hydrogel is 0.5~1 ng / μL, the content of L monomer in the GOFD hydrogel is 375~700 μmol / L, and the content of polydopamine-modified graphene oxide in the GOFD hydrogel is 0.05~0.15 mg / ml.

7. The use of the GOFD hydrogel according to claim 1, characterized in that: Any one or more of the following: 1) Application in the preparation of drugs for promoting cell migration; 2) Application in the preparation of antioxidant drugs; 3) Application in the preparation of drugs promoting angiogenesis; 4) Application in the preparation of radioprotective agents; 5) Application in the preparation of drugs for treating radiation-induced skin damage.

Images